Avidity Biosciences, Inc. (RNA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Avidity Biosciences, Inc. in 2026. The next earnings report is expected on September 2, 2026.
Avidity Biosciences beat consensus estimates in its latest earnings report, with EPS of -$1.18 coming in ahead of the -$1.4175 estimate and revenue of $3 million exceeding estimates by 350.6%. In the prior quarter, both EPS and revenue also came in ahead of expectations.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
